

Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) - Pipeline Review, H2 2017

<https://marketpublishers.com/r/B8803A18778EN.html>

Date: December 2017

Pages: 115

Price: US\$ 3,500.00 (Single User License)

ID: B8803A18778EN

Abstracts

Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) - Pipeline Review, H2 2017

SUMMARY

Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) pipeline Target constitutes close to 38 molecules. Out of which approximately 28 molecules are developed by companies and remaining by the universities/institutes. The latest report Bromodomain Containing Protein 4 - Pipeline Review, H2 2017, outlays comprehensive information on the Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) - Bromodomain-containing protein 4 is a protein encoded by the BRD4 gene. It plays a key role in transmission of epigenetic memory across cell divisions and transcription regulation. It promotes phosphorylation of Ser-2 of the C-terminal domain (CTD) of RNA polymerase II. It acts as a regulator of p53/TP53-mediated transcription. The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 3, 6, 15 and 3 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 5 and 5 molecules, respectively. Report covers products from therapy areas Oncology, Immunology, Cardiovascular, Central Nervous System, Metabolic Disorders, Dermatology, Genetic Disorders, Genito Urinary System And Sex Hormones, Ophthalmology and Respiratory which include indications Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Solid Tumor, Breast Cancer, Multiple Myeloma (Kahler Disease), Diffuse Large B-Cell Lymphoma, Myelodysplastic Syndrome, Ovarian

Cancer, Refractory Acute Myeloid Leukemia, NUT Midline Carcinoma (NMC or Nuclear Protein in Testis Midline Carcinoma), Relapsed Acute Myeloid Leukemia, Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Atherosclerosis, Colorectal Cancer, Follicular Lymphoma, Hematological Tumor, Inflammation, Lung Cancer, Neuroblastoma, Non-Hodgkin Lymphoma, Non-Small Cell Lung Cancer, Refractory Multiple Myeloma, Relapsed Multiple Myeloma, Rheumatoid Arthritis, Small-Cell Lung Cancer, Adenocarcinoma, Advanced Malignancy, Alzheimer's Disease, Atopic Dermatitis, B-Cell Leukemia, B-Cell Non-Hodgkin Lymphoma, Blood Cancer, Chronic Kidney Disease (Chronic Renal Failure), Chronic Lymphocytic Leukemia (CLL), Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia), Colon Cancer, Coronary Artery Disease (CAD) (Ischemic Heart Disease), Fabry Disease, Glioblastoma Multiforme (GBM), Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma), Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Hypercholesterolemia, Idiopathic Pulmonary Fibrosis, Leukemias, Lymphoma, Malignant Pleural Mesothelioma, Melanoma, Metastatic Adenocarcinoma of The Pancreas, Metastatic Brain Tumor, Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Metastatic Liver Cancer, Myelofibrosis, Myeloproliferative Disorders, Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma, Peripheral Arterial Disease (PAD)/Peripheral Vascular Disease (PVD), Peripheral Nerve Sheath Tumor (Neurofibrosarcoma), Pre-Diabetes/Impaired Glucose Tolerance, Prostate Cancer, Psoriasis, Renal Cell Carcinoma, Retinal Degeneration, Substance (Drug) Abuse, Systemic Lupus Erythematosus, Systemic Sclerosis (Scleroderma) and Uveal Melanoma.

Furthermore, this report also reviews key players involved in Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The report provides a snapshot of the global therapeutic landscape for Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4)

The report reviews Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) targeted therapeutics and enlists all their major and minor projects

The report assesses Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) targeted therapeutics

REASONS TO BUY

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Contents

Introduction

Global Markets Direct Report Coverage

Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) - Overview

Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) - Therapeutics

Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) - Therapeutics

Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) - Companies Involved in
Therapeutics Development

Aptose Biosciences Inc

AstraZeneca Plc

Checkpoint Therapeutics Inc

ConverGene LLC

Dybly AG

F. Hoffmann-La Roche Ltd

Forma Therapeutics Inc

GlaxoSmithKline Plc

Kainos Medicine Inc

Mitsubishi Tanabe Pharma Corp

Nuevolution AB

Plexxikon Inc

Red Glead Discovery AB

Resverlogix Corp

Trillium Therapeutics Inc

Zenith Epigenetics Ltd

Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) - Drug Profiles

apabetalone - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

APL-581 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AZD-5153 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

birabresib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CG-202 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CG-223 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CG-250 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CK-103 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CPI-0610 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

dBET-1 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

DCBD-005 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

DYB-186 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

EP-11313 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

FT-1101 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GSK-525762 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

KM-601 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MA-2014 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MS-417 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MZ-1 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NEO-2734 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NUE-7770 - Drug Profile

Product Description
Mechanism Of Action
R&D Progress
PLX-2853 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PLX-51107 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RG-6146 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
S-10 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SBX-1301 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SF-2523 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SF-2535 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit BRD4 for Multiple Myeloma - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit Bromodomain Containing Protein-4 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress

Small Molecules to Inhibit BRD4 and HDAC1 for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit BRD4 for Breast Cancer - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit BRD4 for Malignant Peripheral Nerve Sheath Tumors - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit BRD4 for Ovarian Cancer - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SRX-3177 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TTI-281 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ZBC-260 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ZEN-3694 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) - Dormant Products

Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) - Discontinued Products

Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) - Product Development Milestones

Featured News & Press Releases

Dec 12, 2017: Natures Recent Scientific Reports Publication Describes How

Apabetalone May Be a Powerful Agent Against HIV-1

Nov 27, 2017: Nuevolution to Present New Data on its BET BD1 Program Supporting Effect in Psoriasis/Atopic Dermatitis

Nov 02, 2017: Resverlogix Announces Participation in Upcoming Conferences

Nov 01, 2017: Resverlogix Announces Fifth Positive Recommendation From Data Safety Monitoring Board For Phase 3 Study of Apabetalone

Oct 27, 2017: Nuevolution to present new data on its BET BD1 program supporting the understanding of the biological mode-of-action

Sep 25, 2017: SignalRx Presents in silico Design of Dual PI3K/BRD4 Inhibitors for Combinatorial Activation of Anti-tumor Immunity in Treating Cancer

Aug 29, 2017: Successful CANTOS Inflammation Trial Supports Rationale for Resverlogix Ongoing BETonMACE Trial

Aug 24, 2017: Cancer Drug Can Reactivate HIV

Jul 25, 2017: Resverlogix Receives Approval Pathway from the FDA as to the Inclusion of USA Patients in the Phase 3 BETonMACE Trial

Jul 10, 2017: Resverlogix Randomizes First Patient in Taiwan/China Portion of the Phase 3 BETonMACE Clinical Trial

Jul 05, 2017: Trillium Provides Update on Preclinical Development Program, TTI-281

Jun 28, 2017: Resverlogix Announces Fourth Positive Recommendation From Data Safety Monitoring Board For Phase 3 Study of Apabetalone

Jun 19, 2017: Nuevolution Presents Additional Positive Animal Results in Lupus From its BET Selective Program

Jun 05, 2017: Resverlogix Announces Lead Drug Apabetalone Publication and Presentation at BIO International 2017

Jun 05, 2017: Zenith Announces Issuance of Patent for ZEN-3694 and Presentation Details at BIO International Convention

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development by Stage of Development, H2 2017
Number of Products under Development by Therapy Areas, H2 2017
Number of Products under Development by Indications, H2 2017
Number of Products under Development by Indications, H2 2017 (Contd.1), H2 2017
Number of Products under Development by Indications, H2 2017 (Contd.2), H2 2017
Number of Products under Development by Indications, H2 2017 (Contd.3), H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products under Development by Companies, H2 2017 (Contd.1)
Products under Development by Companies, H2 2017
Products under Development by Companies, H2 2017 (Contd.1), H2 2017
Products under Development by Companies, H2 2017 (Contd.2), H2 2017
Products under Development by Companies, H2 2017 (Contd.3), H2 2017
Products under Development by Companies, H2 2017 (Contd.4), H2 2017
Products under Development by Companies, H2 2017 (Contd.5), H2 2017
Products under Development by Companies, H2 2017 (Contd.6), H2 2017
Number of Products under Investigation by Universities/Institutes, H2 2017
Products under Investigation by Universities/Institutes, H2 2017
Number of Products by Stage and Mechanism of Actions, H2 2017
Number of Products by Stage and Route of Administration, H2 2017
Number of Products by Stage and Molecule Type, H2 2017
Pipeline by Aptose Biosciences Inc, H2 2017
Pipeline by AstraZeneca Plc, H2 2017
Pipeline by Checkpoint Therapeutics Inc, H2 2017
Pipeline by ConverGene LLC, H2 2017
Pipeline by Dybly AG, H2 2017
Pipeline by F. Hoffmann-La Roche Ltd, H2 2017
Pipeline by Forma Therapeutics Inc, H2 2017
Pipeline by GlaxoSmithKline Plc, H2 2017
Pipeline by Kainos Medicine Inc, H2 2017
Pipeline by Mitsubishi Tanabe Pharma Corp, H2 2017
Pipeline by Nuevolution AB, H2 2017
Pipeline by Plexxikon Inc, H2 2017
Pipeline by Red Glead Discovery AB, H2 2017
Pipeline by Resverlogix Corp, H2 2017
Pipeline by Trillium Therapeutics Inc, H2 2017

Pipeline by Zenith Epigenetics Ltd, H2 2017

Dormant Products, H2 2017

Dormant Products, H2 2017 (Contd.1), H2 2017

Discontinued Products, H2 2017

List Of Figures

LIST OF FIGURES

Number of Products under Development by Stage of Development, H2 2017
Number of Products under Development by Therapy Areas, H2 2017
Number of Products under Development by Top 10 Indications, H2 2017
Number of Products by Stage and Mechanism of Actions, H2 2017
Number of Products by Routes of Administration, H2 2017
Number of Products by Stage and Routes of Administration, H2 2017
Number of Products by Stage and Molecule Type, H2 2017

COMPANIES MENTIONED

Aptose Biosciences Inc
AstraZeneca Plc
Checkpoint Therapeutics Inc
ConverGene LLC
Dybly AG
F. Hoffmann-La Roche Ltd
Forma Therapeutics Inc
GlaxoSmithKline Plc
Kainos Medicine Inc
Mitsubishi Tanabe Pharma Corp
Nuevolution AB
Plexxikon Inc
Red Glead Discovery AB
Resverlogix Corp
Trillium Therapeutics Inc
Zenith Epigenetics Ltd

I would like to order

Product name: Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) - Pipeline Review, H2 2017

Product link: <https://marketpublishers.com/r/B8803A18778EN.html>

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/B8803A18778EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970